TOBRAMYCIN SULFATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1975)
Entry Type: Small molecule
Molecule Category: Salt
UNII: HJT0RXD7JK
Parent Compound: TOBRAMYCIN

Structure
InChI Key ZEUUPKVZFKBXPW-TWDWGCDDSA-N
Smile NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O.O=S(=O)(O)O
InChI
InChI=1S/C18H37N5O9.H2O4S/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18;1-5(2,3)4/h5-18,24-28H,1-4,19-23H2;(H2,1,2,3,4)/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+;/m0./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C36H84N10O38S5
Molecular Weight 1425.44
AlogP -6.3
Hydrogen Bond Acceptor 14.0
Hydrogen Bond Donor 10.0
Number of Rotational Bond 6.0
Polar Surface Area 268.17
Molecular species BASE
Aromatic Rings 0.0
Heavy Atoms 32.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR 70S ribosome inhibitor FDA PubMed Wikipedia

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Osteomyelitis 0 D010019 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Renal and urinary disorders
18.91
General disorders and administration site conditions
13.69
Injury, poisoning and procedural complications
11.1
Investigations
7.17
Nervous system disorders
6.03
Immune system disorders
5.77
Skin and subcutaneous tissue disorders
5.28
Respiratory, thoracic and mediastinal disorders
5.23
Infections and infestations
4.9
Gastrointestinal disorders
3.77
Vascular disorders
3.45
Ear and labyrinth disorders
3.02
Metabolism and nutrition disorders
2.59

Cross References

Resources Reference
ChEMBL CHEMBL3989564
FDA SRS HJT0RXD7JK
PubChem 11954252
CONTENTS